Abstract：
BACKGROUND: Enfortumab vedotin (EV) is an antibody-drug conjugate directed against Nectin-4 that is used to treat urothelial carcinoma. Nectin-4 is inherently expressed in the skin and adnexal structures. Since therapeutic options for cutaneous adnexal carcinomas are limited, we sought to evaluate Nectin-4 expression in adnexal carcinomas and benign adnexal neoplasms to identify tumors that are potentially targetable with EV.
METHODS: Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti-Nectin-4 antibody. H-scores for Nectin-4 expression were calculated.
RESULTS: Benign adnexal neoplasms had a significantly lower mean (±SD) Nectin-4 H-score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin-4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin-4 (88% [7/8]), with a mean (±SD) H-score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H-scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013).
CONCLUSIONS: Increased Nectin-4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors.
METHODS: Eight sebaceous carcinomas (seven periocular and one lymph node metastasis), eight digital papillary adenocarcinomas, seven squamoid eccrine ductal carcinomas, eight poromas, eight trichilemmomas, and seven sebaceous adenomas were subjected to immunohistochemical staining for anti-Nectin-4 antibody. H-scores for Nectin-4 expression were calculated.
RESULTS: Benign adnexal neoplasms had a significantly lower mean (±SD) Nectin-4 H-score (142.6 ± 39.1) than did the adnexal carcinomas (198 ± 90.8; p = 0.006). Nectin-4 was expressed in 91% (21/23) of adnexal carcinomas. Sebaceous carcinomas frequently exhibited high expression of Nectin-4 (88% [7/8]), with a mean (±SD) H-score (258.1 ± 58.4) significantly higher than those for digital papillary adenocarcinomas (197.5 ± 52.5; p = 0.035) and squamoid eccrine ductal carcinomas (131.4 ± 114.1; p = 0.031). Sebaceous carcinomas also had significantly higher H-scores than did sebaceous adenomas (186.4 ± 25.0; p = 0.013).
CONCLUSIONS: Increased Nectin-4 expression in a subset of cutaneous adnexal carcinomas, particularly sebaceous carcinomas, reveals that EV is a potential therapeutic option for these tumors.
摘要：
背景：Enfortumabvedotin（EV）是一种针对Nectin-4的抗体-药物偶联物，用于治疗尿路上皮癌。Nectin-4固有地在皮肤和附件结构中表达。由于皮肤附件癌的治疗选择有限，我们试图评估Nectin-4在附件癌和良性附件肿瘤中的表达,以鉴定具有EV潜在靶向性的肿瘤.
方法：8例皮脂腺癌（7例眼周转移，1例淋巴结转移），八个数字乳头状腺癌，七个鳞状内分泌导管癌，八个Pormas,八个三色肌,对7个皮脂腺腺瘤进行抗Nectin-4抗体的免疫组织化学染色。计算Nectin-4表达的H-评分。
结果：良性附件肿瘤的平均（±SD）Nectin-4H评分（142.6±39.1）明显低于附件癌（198±90.8；p=0.006）。Nectin-4在91%(21/23)的附件癌中表达。皮脂腺癌经常表现出Nectin-4的高表达（88%[7/8]），平均（±SD）H评分（258.1±58.4）显着高于数字乳头状腺癌（197.5±52.5；p=0.035）和鳞状内分泌导管癌（131.4±114.1；p=0.031）。皮脂腺癌的H评分也明显高于皮脂腺腺瘤（186.4±25.0；p=0.013）。
结论：Nectin-4在皮肤附件癌子集中表达增加，尤其是皮脂腺癌，揭示了EV是这些肿瘤的潜在治疗选择。
方法：8例皮脂腺癌（7例眼周转移，1例淋巴结转移），八个数字乳头状腺癌，七个鳞状内分泌导管癌，八个Pormas,八个三色肌,对7个皮脂腺腺瘤进行抗Nectin-4抗体的免疫组织化学染色。计算Nectin-4表达的H-评分。
结果：良性附件肿瘤的平均（±SD）Nectin-4H评分（142.6±39.1）明显低于附件癌（198±90.8；p=0.006）。Nectin-4在91%(21/23)的附件癌中表达。皮脂腺癌经常表现出Nectin-4的高表达（88%[7/8]），平均（±SD）H评分（258.1±58.4）显着高于数字乳头状腺癌（197.5±52.5；p=0.035）和鳞状内分泌导管癌（131.4±114.1；p=0.031）。皮脂腺癌的H评分也明显高于皮脂腺腺瘤（186.4±25.0；p=0.013）。
结论：Nectin-4在皮肤附件癌子集中表达增加，尤其是皮脂腺癌，揭示了EV是这些肿瘤的潜在治疗选择。
